$TYRA

Tyra Biosciences (TYRA) reported positive Phase 2 results for dabogratinib in LG IR NMIBC, showing 79% ORR and 64% CR rate at 60 mg QD. The company plans Phase 3 studies and further evaluation in the ablative setting. Dabogratinib demonstrated favorable safety and tolerability. TYRA stock is down 31.72% in pre-market trading.

US equity futures fell as Brent crude oil topped $100, pushing 10-year Treasury yields above 4.81%. Meta (META) rose 5% on strong AI usage, while other Mag 7 stocks traded mixed. Braze (BRZE) dropped 11% on weak earnings forecasts, and ServiceTitan (TTAN) fell 17% on revenue concerns. Chime (CHYM) gained 9% after acquiring Stride Bank. Oil prices surged after US strikes on Iranian tankers, and Treasury Secretary Scott Bessent challenged traders on yen strength. Barclays raised its S&P 500 target

Tyra Biosciences (TYRA) stock fell 31.1% to $18.42 after Phase 2 trial results for dabogratinib showed a 64% complete response rate, below the 70% analyst consensus. Piper Sandler and H.C. Wainwright had modeled a 70% rate as the success threshold. The stock had risen 13% the prior week. Broader market caution added to the decline.

Piper Sandler reiterated an Overweight rating and $56 price target for Tyra Biosciences (NASDAQ: TYRA) ahead of clinical trial data. The stock has risen 13% in a week and 136% in a year, trading at $28.60. Piper Sandler expects a 70% response rate for dabogratinib in bladder cancer trials, which could advance the drug to Phase 3. The firm sees a $1B+ opportunity in this market. Other analysts also maintain Buy ratings with targets up to $45.

Tyra Biosciences (Nasdaq: TYRA) reported Q2 2026 results and updates on oral dabogratinib. Initial Phase 2 SURF302 data are expected in September 2026, and BEACH301 safety sentinel results are expected end of Q1 2027. Cash, cash equivalents and marketable securities were $353.9M, runway into 2H 2028. Q2 net loss was $45.6M.

Tyra Biosciences, Inc. (TYRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including

Wolfe Research initiated coverage of Tyra Biosciences (NASDAQ:TYRA) with a Peer Perform rating and no price target on May 19, saying dabogratinib could meet the CR bar for LR IR NMIBC but remains dependent on safety de-risking. Tyra’s May 13 Q1 update reported a $39.3M net loss, $383.5M cash, and funding into 2H 2028.

Wolfe Research initiated coverage of Tyra Biosciences, Inc. (TYRA) with a “Peer Perform” rating, according to the article. The piece also discusses broader AI and robotics themes and cites comments from figures including Jeff Bezos, Andy Jassy, and Elon Musk, but provides no TYRA financial figures or price targets.

This article reports on a Form 144 SEC filing by Tyra Biosciences, Inc. (TYRA) related to a proposed sale of securities. The filing details include information about the filer, the issuer, the class of securities being sold (Common stock), the aggregate market value, and previous sales by Daniel Bensen. The filing also mentions the relationship of the seller to the issuer and provides a detailed breakdown of the acquisition of the securities.

This page provides a comprehensive resource for Tyra Biosciences SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event forms, and insider trading forms. Tyra Biosciences is a clinical-stage biotechnology company focusing on precision medicines. The site offers AI-powered summaries to highlight key disclosures, clinical trial milestones, and financial commentary.